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Abstract CD1d-restricted natural killer T (NKT)
cells expressing invariant V14J18 T cell receptor -
chains are abundant in murine liver and are implicated
in the control of malignancy, infection and autoimmu-
nity. Invariant NKT cells have potent anti-metastatic
eVects in mice and phase I clinical trials involving their
homologues in humans are ongoing. However, invari-
ant NKT cells are less abundant in human liver (»0.5%
of hepatic T cells) than in murine liver (up to 50%) and
it is not known if other hepatic T cells are CD1-
restricted. We have examined expression of CD1a,
CD1b, CD1c and CD1d mRNA and protein in human
liver and evaluated the reactivity of mononuclear cells
(MNC) from histologically normal and tumour-bearing
human liver specimens against these CD1 isoforms.
Messenger RNA for all CD1 isotypes was detectable in
all liver samples. CD1c and CD1d were expressed at
the protein level by hepatic MNC. CD1d, only, was
detectable at the cell surface, but CD1c and CD1d
were found at an intracellular location in signiWcant
numbers of liver MNC. CD1b was not expressed by
MNC from healthy livers but was detectable within
MNC in all tumour samples tested. Hepatic T cells
exhibited reactivity against C1R cells expressing trans-
fected CD1c and CD1d, but neither CD1a nor CD1b.
These cells secreted interferon- (IFN-) but not inter-
leukin-4 (IL-4) upon stimulation. In contrast, similar
numbers of peripheral T cells released 13- and 16-fold
less IFN- in response to CD1c and CD1d, respec-
tively. CD1c and CD1d expression and T cell reactivity
were not altered in tumour-bearing liver specimens
compared to histologically normal livers. These data
suggest that, in addition to invariant CD1d-restricted
NKT cells, autoreactive T cells that recognise CD1c
and CD1d and release inXammatory cytokines are
abundant in human liver.
Keywords Human · Liver · T cells · Natural killer T 
cells · Tumour immunity
T. Kenna · M. O’Brien · C. O’Farrelly
Education and Research Centre, St. Vincent’s University 
Hospital, Elm Park, Dublin 4, Ireland
A. E. Hogan · D. G. Doherty (&)
Institute of Immunology and Department of Biology, 
National University of Ireland, Maynooth, Maynooth, 
Co. Kildare, Ireland
e-mail: derek.g.doherty@nuim.ie
M. A. Exley
Cancer Biology Program, Hematology and Oncology 
Division, Beth Israel Deaconess Medical Center and Harvard 
Medical School, Boston, MA, USA
S. A. Porcelli
Department of Microbiology and Immunology, 
Albert Einstein College of Medicine, New York, NY, USA
J. E. Hegarty
Liver Unit, St. Vincent’s University Hospital, Elm Park, 
Dublin 4, Ireland
J. E. Hegarty · C. O’Farrelly
Conway Institute of Biomolecular and Biomedical Research, 
University College Dublin, Dublin 4, Ireland
Present Address:
T. Kenna
Centre for Immunology & Cancer Research, 
The University of Queensland, Princess Alexandra Hospital, 
Woolloongabba, Australia123
564 Cancer Immunol Immunother (2007) 56:563–572Abbreviations
GC -Galactosylceramide
ELISA Enzyme-linked immunosorbent assay
GAPDH Glyceraldehyde phosphate dehydrogenase
IL Interleukin
IFN- Interferon-
MAb Monoclonal antibody
MHC Major histocompatibility complex
MNC Mononuclear cells
NK Natural killer
NKT Natural killer T
PCR Polymerase chain reaction
TCR T cell receptor
Introduction
CD1 molecules comprise a family of glycoproteins that
share structural similarities with major histocompati-
bility complex (MHC) molecules and are specialised in
the presentation of lipid antigens to T cells [7, 46].
CD1-restricted T cells play key roles in anti-tumour
defence in mice. SpeciWc activation of these cells in
vivo results in rapid anti-tumour cytotoxicity and IFN-
 production, which can prevent tumour metastasis and
promote tumour rejection [14, 28, 41, 50]. CD1-
restricted T cells are therefore potential targets for
immunotherapy for cancer and phase I trials using
CD1-binding glycolipids are ongoing [25, 42].
Most therapeutic studies involving CD1-restricted
T cells have been conWned to the use of a population
of CD1d-restricted T cells which expresses natural
killer (NK) cell receptors and a T cell receptor (TCR)
consisting of an invariant -chain (V14J18 in mice
and V24J18 in humans), which pairs with one of a
limited number of -chains [25, 42]. In both species,
these “invariant” NKT cells display rapid and potent
cytolytic activity and secretion of cytokines (IFN-,
IL-2, IL-4 and IL-10), which direct adaptive immune
responses [4, 7, 11, 19, 51]. In mice, invariant
V14J18+ NKT cells generally account for »5% of
peripheral blood T cells but they are highly enriched in
liver, accounting for 30–50% of all T cells at this loca-
tion [4, 18]. In contrast, human invariant NKT cells
expressing the homologous V24J18 TCR -chain are
found in signiWcantly lower numbers in human blood
(»0.02% of T cells) and liver (»0.5%) [30, 33, 38] and
immunotherapy involving invariant NKT cells is less
eYcacious than in mice [25, 42]. However, T cells
expressing the NK-associated receptors, CD56, CD161,
CD94 and killer Ig-like receptors are substantially
enriched in adult human liver [16, 43]. Like NKT cells,
they display potent cytolytic activity and prompt cyto-
kine secretion but they do not carry invariant TCR
chains. It is not known if these NK-like T cells include
functional equivalents of murine NKT cells. If they do
they could be important potential targets for cancer
immunotherapy, based on studies on murine disease
models [14, 28, 41, 50].
While mice encode a single CD1 isoform, CD1d,
humans have Wve isoforms, CD1a–e, of which CD1a,
CD1b, CD1c and CD1d have been shown to stimulate
T cells. CD1a, b and c are expressed by dendritic cells
and other antigen-presenting cells and can present a
range of lipids (mycolic acids, mycolates esteriWed to
simple sugars, phosphatidyl inositol moieties linked
to complex glycans, polyisoprenoid lipids and lipo-
peptides) derived from the cell walls of mycobacteria
to T cells [7, 46]. CD1d is expressed by various mye-
loid, epithelial, parenchymal, and vascular smooth
muscle cells in non-lymphoid organs [7, 10, 39, 46]
and can present the -anomeric glycolipid, -galacto-
sylceramide (GC), found in marine sponges [31] and
glycosphingolipids from Gram-negative bacteria that
do not contain lipopolysaccharide [34] to subsets of T
cells. Many CD1-restricted T cells can also be stimu-
lated by exposure to antigen-presenting cells express-
ing CD1a, CD1b, CD1c or CD1d in the absence of
added antigen [19, 45]. This autoreactivity probably
results from T cell recognition of endogenous lipid
antigens, such as phospholipids, gangliosides, sulphat-
ides and the lysosomal glycosphingolipid, isoglobo-
trihexosylceramide, which have been shown to bind
to human and murine CD1 and activate CD1-
restricted T cells [27, 48, 49, 60].
To ascertain whether the human liver contains func-
tional equivalents of murine invariant CD1d-restricted
T cells, we have examined the expression of CD1a,
CD1b, CD1c and CD1d mRNA and protein in liver
samples taken from healthy donors and patients with
hepatic malignancy. Since there are no deWning pheno-
typic markers for T cells restricted by CD1a, CD1b and
CD1c [7, 26, 46, 53] and non-invariant CD1d-restricted
T cells which express diverse  or  TCRs with multi-
ple rearranged junctional sequences have been
described [3, 12, 21, 44], we have evaluated the reactiv-
ity of hepatic T cells against a panel of transfectant
cells expressing CD1a, CD1b, CD1c and CD1d. Our
data indicate that, although invariant NKT cells consti-
tute only a small proportion of human hepatic T cells,
CD1c and CD1d are expressed by signiWcant numbers
of liver MNC, and autoreactive T cells that recognise
CD1c and CD1d and release inXammatory cytokines
are abundant in normal and tumour-bearing human
liver. We also have found that CD1b is expressed in
MNC from tumour-bearing but not normal liver.123
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Tissue specimens
Wedge liver biopsies (50–100 mg) were obtained from
14 healthy donor organs at the time of liver transplan-
tation. Liver biochemistry and histology were normal
in all cases. Liver tissue was also obtained from 15
patients undergoing resection for hepatic metastases of
colonic origin. Wedge biopsies from tumour-bearing
tissue were taken approximately 10 cm from the
tumour margin and appeared histologically normal. All
organ donors and patients were negative for hepatitis
A, B, C,  and E viruses. Blood samples were obtained
from seven healthy donors. Ethical approval for this
study was obtained from the Research and Ethics
Committee at St. Vincent’s University Hospital, Dub-
lin, Ireland.
Preparation of peripheral blood and liver MNC
Mononuclear cells were prepared from anti-coagu-
lated whole blood by Lymphoprep (Nycomed, Oslo,
Norway) density gradient centrifugation. Single liver
cell suspensions, which contain MNC and residual
parenchymal cells, were prepared as previously
described [43]. CD3+ cells were isolated from fresh
hepatic and peripheral MNC preparations by positive
selection using monoclonal antibody (mAb)-coated
magnetic beads (Miltenyi Biotec, Bergisch Gladbach,
Germany). The purity of isolated fractions was
assessed by Xow cytometry and only preparations
with purities of 95% or greater were used for func-
tional studies.
Analysis of CD1 mRNA
RNA was isolated from snap frozen liver specimens
using the Rneasy Mini Kit (Qiagen, Crawley, UK) and
reverse transcribed into cDNA using Superscript II
(Promega, Madison, WI). Polymerase chain reaction
(PCR) ampliWcation of CD1a, CD1b, CD1c and CD1d
was carried out in separate 25 l reactions containing
1 l cDNA with the following oligonucleotide primer
pairs (forward and reverse) [29, 54]: 
CD1a, ATGCTGTTTTTGCTACTTCCATTGTTA
and CGTGGGCAGGTGTCACTGAGAAG,
CD1b, ATGCTGCTGCTGCCATTTCAACTGT
TA and GGGCAGGTTTCATAGAGGAGAAT
TC,
CD1c, ATGCTGTTTCTGCAGTTTCTGCTGCT
A and CTGTTTCTGTGACGCCTTCATACTG,
CD1d, GCTCCACCAGGACAAGTGGACGAG
and GGAGGTAAAGCCCACAATGAGGAG.
These primers produced products of 530, 528, 529
and 535 bp, respectively. Thermocycling conditions
consisted of an initial incubation at 94°C for 10 min to
activate the polymerase enzyme (AmpliTaq Gold,
Gibco BRL Life Technologies, Paisley, UK) followed
by 30 cycles consisting of 1 min at 94°C, 2 min at 60°C,
and 2 min at 72°C. As a control, PCR was performed
on all samples using primers speciWc for the house-
keeping gene glyceraldehyde phosphate dehydroge-
nase (GAPDH), GCCTCAAGATCATCAGCAA
and CCAGCGTCAAAGGTGGAG.
Antibodies and Xow cytometry
The expression of CD1 protein by liver cells in single
cell suspensions was determined by Xow cytometry
using the unconjugated mAbs, 10H3.9.3 (CD1a),
BCD1b3 (CD1b), F10/21A3 (CD1c) and CD1d51
(CD1d), which we have previously generated [20, 26].
BrieXy, 105 cells were incubated with 0.2 g antibody
for 20 min at 4°C and washed twice in PBA buVer
(PBS containing 1% bovine serum albumin and 0.02%
sodium azide). The cells were then incubated for
20 min at 4°C with 5 l of a 1/5 dilution of rabbit anti-
mouse immunoglobulin conjugated to Xuorescein iso-
thiocyanate (Dako, Cambridge, UK), washed as
before, and incubated for 15 min at 4°C with 50 l of a
1/25 dilution of Wltered normal mouse serum (Vector
Laboratories, Peterborough, UK). Cells were washed
twice in PBA buVer and analysed immediately on a
FACScan Xow cytometer (Becton Dickinson, Oxford,
UK). The expression of CD1 by lymphocytes and non-
lymphocytes within MNC was assessed by electronic
gating of the lymphocytes which display lower forward
and side scatter. C1R cell lines transfected with the
individual CD1 isoforms [19] were used as positive
controls for mAb staining. Intracellular CD1 was
detected by Wxing cells with 4% paraformaldehyde and
permeabilising them with 0.2% saponin (Sigma-Ald-
rich, Dublin, Ireland) before adding the anti-CD1
mAbs [16].
Assessment of hepatic T cell reactivity against
CD1 in vitro
PuriWed hepatic or peripheral CD3+ cells (6 £ 104
cells) were cultured in triplicate in medium alone,
with phytohaemagglutinin, or with equal numbers of
mock-transfected C1R cells or C1R cells transfected
with CD1a, CD1b, CD1c or CD1d [19] in complete123
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20 IU/ml recombinant human IL-2 (National Cancer
Institute—Frederick Research Foundation Biological
Resources Branch) and 1 ng/ml phorbol myristate ace-
tate (Sigma-Aldrich) in a Wnal volume of 250 l. For
CD1 blocking experiments, the C1R-CD1 transfectants
were Wrst mixed with 1.0 g/ml of the relevant mAb or
isotype matched control antibody before addition of T
cells. After 48–72 h supernatants were removed for
analysis of IFN- and IL-4 production by enzyme-
linked immunosorbent assays (ELISA) using mAb
pairs obtained from R&D Systems (Abingdon, UK).
The invariant NKT cell line, LPK 89 [23], was used as a
positive control for in vitro CD1d-reactivity.
Statistical analyses
Mean Xuorescence intensities and cytokine levels were
compared using the unpaired Student’s t test and P val-
ues of <0.05 were considered signiWcant.
Results
Expression of CD1 mRNA in human liver
PCR ampliWcation of reverse transcribed mRNA was
used to analyse the presence of CD1a, CD1b, CD1c
and CD1d transcripts in normal (n = 14) and tumour-
bearing (n = 15) liver samples. Representative results
for four normal and three tumour-bearing liver sam-
ples are shown in Fig. 1. CD1a transcripts were found
to be variably present in all liver samples examined.
CD1b, CD1c and CD1d mRNA were found to be
abundant in whole liver samples from both normal and
tumour-bearing tissue (Fig. 1).
Expression of CD1 protein by human liver MNC
The expression of CD1a, CD1b, CD1c and CD1d
protein isoforms by freshly isolated hepatic MNC was
examined by mAb staining and Xow cytometry. Mock-
transfected C1R cells and C1R cells transfected with
CD1a, CD1b, CD1c or CD1d were used as positive
controls for mAb staining (Fig. 2a). While CD1a, b and
c were not expressed at the cell surface of MNC from
Wve normal liver samples tested, CD1d was weakly
expressed (Fig. 2b, c). No induction or reduction of cell
surface expression of any of the CD1 isoforms was
detected in Wve samples of tumour-bearing liver cells
(Fig. 2c).
To detect whether CD1 isoforms are expressed
intracellularly, cell suspensions from Wve normal livers
were permeabilised with saponin before mAb staining
and analysed by Xow cytometry (Fig. 2b). In all sam-
ples from healthy livers CD1a and CD1b expression
was undetectable following permeabilisation, but sig-
niWcant CD1c and CD1d staining was seen (Fig. 2d).
Separate analysis of the lymphocyte and non-lympho-
cytes within the liver cell suspensions by electronic gat-
ing indicated that both fractions stained positive for
CD1c and CD1d (data not shown). Analysis of MNC
from Wve tumour-bearing livers showed low but signiW-
cantly increased intracellular expression of CD1b
(P = 0.002) and slightly elevated cell-surface and intra-
cellular expression of CD1d. The changes in CD1d
expression were not signiWcant (Fig. 2c, d).
Hepatic T cell responses to CD1 isoforms
Since CD1 isoforms are expressed in human liver, we
next determined whether CD1-reactive T cells were
detectable in liver. IFN- and IL-4 secretion by CD3+
cells puriWed from Wve normal donor livers in response
to mock-transfected C1R cells or C1R cells transfected
with CD1a, CD1b, CD1c or CD1d was measured by
ELISA. The levels of cell-surface CD1 expression by
the C1R cells used as stimulators were shown by Xow
cytometry to be comparable for all CD1 isoforms
(Fig. 2a). Figure 3a shows that minimal responses,
Fig. 1 Expression of CD1a, CD1b, CD1c and CD1d mRNA in
whole human liver samples. Reverse transcription-PCR analysis
of CD1a–d and, as a control, glyceraldehyde phosphate dehydro-
genase (GAPDH) expression in four normal and three represen-
tative tumour-bearing liver samples. Results are representative of
14 normal and 15 tumour-bearing liver samples
CD1a
CD1b
CD1c
GAPDH
Normal liver
samples
Tumor-bearing
liver samples
CD1d123
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CD1a and CD1b transfectants as stimulators in IFN-
and IL-4 assays. In contrast, hepatic CD3+ cells from
normal liver responded to CD1c and CD1d by releas-
ing IFN- (means 2.37 ng/ml for CD1c and 4.76 ng/ml
for CD1d). In all Wve normal samples tested, the
CD1d-speciWc IFN- response was comparable to the
response to mitogen stimulation of the same cells
(3.94 ng/ml) and CD1d stimulation of the human
blood-derived invariant NKT cell line, LPK.89. These
IFN- levels are signiWcantly higher than those
obtained when similar numbers of peripheral blood
CD3+ cells were similarly stimulated. Means of 0.17,
0.13, 0.18 and 0.3 ng/ml IFN- (n = 3 samples) were
released by peripheral blood T cells in response to C1R
cells expressing transfected CD1a, CD1b, CD1c and
CD1d, respectively (Fig. 3a, upper central panel).
No IL-4 was released by hepatic CD3+ cells stimu-
lated with any of the CD1 isoforms. This contrasts with
our observations of IL-4 production (mean 121 pg/ml)
by hepatic CD3+ cells in response to phytohaemagglu-
tinin stimulation, and by the invariant NKT cell line,
LPK.89 (436 pg/ml), in response to CD1d. IL-4 release
by CD3+ PBMC in response to CD1 was not investi-
gated, but undetectable levels of another Th2 cytokine,
IL-13, were released peripheral T cells in response to
each CD1 isoform (data not shown).
Conformational CD1-speciWc and control mAb
blocking experiments were used to determine the
speciWcity of the interaction between hepatic CD3+
cells and CD1c and CD1d and to test whether
responses were speciWc for intact CD1 rather than
CD1 peptides presented indirectly by MHC mole-
cules (Fig. 3b). Incubation of the transfectants with
Fig. 2 Expression of CD1a, 
CD1b, CD1c and CD1d pro-
tein by freshly isolated human 
liver mononuclear cells 
(MNC). a Flow cytometric 
evaluation of the expression 
of transfected CD1a, CD1b, 
CD1c and CD1d by the C1R 
cells used in the present study. 
b Representative Xow cytom-
etry histograms showing cell-
surface (top) and intracellular 
(bottom) CD1a–d expression 
by human hepatic MNC. 
Mean Xuorescence intensities 
of cell-surface (c) and intra-
cellular (d) staining of MNC 
from Wve histologically 
normal liver samples (open 
circles) and Wve liver samples 
taken from patients with 
hepatic malignancy (closed 
circles) with mAbs speciWc for 
CD1a–d after subtraction of 
mean Xuorescence intensities 
obtained using isotype-
matched antibody controls
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(CD1d51) mAbs prior to addition of T cells almost
completely blocked CD1-induced IFN- production
by hepatic CD3+ cells. Therefore, the T cell reactivity
against C1R cells expressing CD1c or CD1d is CD1-
speciWc and not a result of recognition of the peptide
fragments derived from these molecules presented by
MHC molecules.
CD1-reactive T cells in tumour-bearing liver
IFN- and IL-4 secretion by CD3+ cells puriWed from
Wve tumour-bearing liver specimens in response to
mock-transfected C1R cells and C1R cells transfected
with CD1a, CD1b, CD1c and CD1d was also measured
by ELISA. Figure 4 illustrates that, like normal liver,
tumour-bearing liver also contains IFN--producing T
cells that are reactive against CD1c and CD1d, but nei-
ther CD1a nor CD1b. The levels of IFN- produced by
hepatic T cells in response to CD1c were similar in
tumour-bearing (means 2.9 ng/ml, range 1.28–5.64 ng/
ml) and normal (2.37 ng/ml, range 1.07–4.13 ng/ml) liv-
ers. IFN- production by hepatic T cells in response to
CD1d stimulation appeared to be slightly lower using
cells derived from tumour-bearing tissue (3.2 ng/ml,
range 1.11–8.64) compared with normal hepatic T cells
(4.8 ng/ml, range 3.04–8.21 ng/ml), but this diVerence
was not signiWcant (P > 0.05). As with normal hepatic
CD3+ cells, T cells derived from tumour-bearing livers
did not produce measurable IL-4 in response to CD1
stimulation but were capable of comparable IL-4 secre-
tion upon mitogenic stimulation (Fig. 4).
Discussion
Murine liver contains large numbers of CD1d-restricted
invariant NKT cells, with up to 50% of intrahepatic
Fig. 3 Human hepatic T cell 
reactivity against CD1a, 
CD1b, CD1c and CD1d. a 
IFN- (top) and IL-4 (bottom) 
release by hepatic CD3+ cells 
(left), peripheral blood CD3+ 
cells (centre) and the CD1d-
restricted NKT cell line, 
LPK.89 (right) in response to 
mock-transfected C1R cells, 
C1R cells transfected with 
CD1a, CD1b, CD1c or CD1d, 
or phytohaemagglutinin 
(PHA). b IFN- release by 
hepatic CD3+ cells in response 
to mock-transfected C1R 
cells, C1R cells transfected 
with CD1c or CD1d in the 
presence of F10/21A3 
(anti-CD1c mAb), CD1d51 
(anti-CD1d mAb), 
or isotype-matched control 
antibody. Results are means 
of Wve normal liver and seven 
blood samples
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TCR -chains [4, 18]. Invariant NKT cells display
potent cytolytic activity and the rapid secretion of Th1
(IFN-), Th2 (IL-4 and IL-13) and immunosuppressive
(IL-10) cytokines, making them potential regulators of
adaptive immune responses [4, 11, 19, 51]. They can
play key roles in immune defence against viruses, bacte-
ria, fungi, parasites and tumours and the prevention of
autoimmune disease in various mouse models [7, 28].
NKT cells are therefore under scrutiny as potential tar-
gets for immunotherapy for cancer, and multiple clini-
cal trials using GC are under way [25, 42].
In contrast to murine NKT cells, the roles of CD1d-
restricted T cells in hepatic immunoregulation and
anti-tumour immunity in the human are less clear.
Humans have invariant CD1d-restricted NKT cells
expressing V24J18 TCR -chains, with similar anti-
gen speciWcities and functional activities to murine
invariant NKT cells [19], but which are found in signiW-
cantly lower numbers in liver (»0.5% of T cells) and
blood (»0.02%) compared to their murine counter-
parts [30, 33, 38]. However, the human liver contains
large numbers of T cells with diverse TCRs that
express NK cell receptors and display NK-like func-
tional activities [16, 43]. It is possible that hepatic T
cells include cells that use non-invariant TCRs to rec-
ognise CD1d or the other CD1 isotypes, CD1a–c,
which are not found in mice. We have addressed this
hypothesis by examining CD1 isotype expression and
T cell reactivity to CD1a, CD1b, CD1c and CD1d in
healthy and tumour-bearing human livers.
We report that CD1a, CD1b, CD1c and CD1d
mRNA were detectable in all adult human liver speci-
mens tested. CD1a and CD1b proteins were not
detected at the cell surface or within hepatic MNC from
Wve normal livers tested. The Wnding of CD1a and
CD1b mRNA but not protein expression suggests that
these CD1 isoforms may be expressed by other liver
cells. CD1b was expressed intracellularly in Wve of Wve
tumour-bearing livers, suggesting that CD1b-restricted
T cells may play a role in immunity against tumours.
CD1c and CD1d were expressed at very low levels
at the cell surface, but were found at an intracellular
location in signiWcant numbers of liver MNC from all
samples tested, including lymphocytes and non-lympho-
cytes. Previous work has shown that CD1d is most
prominently expressed by intestinal epithelial cells [2, 6],
thymocytes and haematopoietic-derived cells [9, 20] but
it has also been reported to be expressed inside hepato-
cytes in mice [6, 39] and by hepatocytes, cholangiocytes
and hepatic MNC in humans with inXammatory dis-
eases of the liver [1, 10, 17, 36, 57]. While CD1d expres-
sion does not appear to be induced by individual
cytokines or growth factors [52], the intracellular loca-
tion of CD1d in normal human liver, found in the pres-
ent study, suggests that MNC surface expression of
CD1d may be rapidly induced by translocation to the
cell surface. Future studies are required to determine
what signals may mediate this process. We have also
detected intracellular, but not cell surface, expression of
CD1c by liver MNC, suggesting that this CD1 isoform
may also be similarly translocated to the cell surface in
response to as yet unknown signals. CD1c is known to
be expressed by dendritic cells and B cells [7, 46], which
are abundant in liver.
In addition to our Wnding that CD1c and CD1d are
the only CD1 isoforms that show signiWcant expression
in human liver MNC, we found that hepatic T cell reac-
tivity against CD1, expressed by C1R cells, was limited
to CD1c and CD1d. Stimulation of T cells from a total
of ten liver samples with C1R cells expressing CD1c or
CD1d resulted in means of 13-fold and 16-fold more
IFN- release, respectively, than for stimulation of sim-
ilar numbers of peripheral blood T cells. Little or no
IFN- was released by hepatic T cells in response to
CD1a and CD1b. Although it is possible that the trans-
fected C1R cells used in the present study have altered
antigen-presenting properties compared to natural
antigen-presenting cells, our results suggest that
hepatic T cell recognition of CD1 is limited to CD1c
and CD1d. CD1d-reactivity of human hepatic T cells
from patients with chronic hepatitis C virus infection
Fig. 4 CD1 reactivity of hepatic T cells from normal donors and
patients with hepatic malignancy. IFN- (left) and IL-4 (right) re-
lease by hepatic CD3+ cells from donor organs used for transplan-
tation and resected liver tissue from patients with hepatic
malignancy in response to mock-transfected C1R cells, C1R cells
transfected with CD1a, CD1b, CD1c or CD1d, or PHA. Results
are means of Wve normal and Wve tumour liver specimens
0 2 4 6 8
C1R Mock
C1R CD1b
C1R CD1c
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C1R CD1d
C1R CD1a
IFN- γ (ng/ml)
0 50 100 150
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is presumably mediated, in part, by invariant
V24V11+ NKT cells [30, 33, 38] but invariant NKT
cells were found to account for only 0.5% of hepatic T
cells [33]. Their low numbers in human liver despite
strong CD1d reactivity suggests that other non-invari-
ant CD1d-restricted T cells may predominate. CD1d-
restricted NKT cells with diverse TCRs have been
described in mice and humans [3, 21, 22, 44] and it is
thought that invariant and non-invariant NKT cells
sample antigens in diVerent endosomal compartments
[12]. Future work is required to determine which T cell
subpopulations recognise CD1d; however, previous
studies have shown that the human liver harbours sev-
eral subsets of T cells that, like invariant NKT cells,
express NK receptors and mediate NK-like cytotoxic-
ity [16, 32, 33, 43]. Recognition of GC is primarily,
although not exclusively, restricted to invariant NKT
cells [5, 24, 30]; therefore, therapies based on GC
would be less eYcacious in humans compared to
mouse models.
Murine and human invariant NKT cells are notable
for their ability to rapidly secrete IFN- and IL-4 upon
stimulation with CD1d [4, 11, 19, 51]. The production
of these cytokines, which have opposing eVects of Th
cell diVerentiation, implicates invariant NKT cells as
drivers and regulators of adaptive immune responses.
However, we have found that human hepatic T cells
speciWcally release IFN- only in response to CD1d-
expressing C1R cells. The lack of IL-4 production in
this in vitro system is consistent with previous Wndings
on human hepatic CD1d-reactive and V24V11+ T
cells [21, 33] but contrasts with those on CD1d-reactive
T cells from human blood [19] and bone marrow [22].
These diVerences suggest that CD1d-reactive T cells
may have diVerent immunoregulatory roles in diVerent
tissues.
Our observation that human hepatic T cells exhibit
signiWcant reactivity against CD1c indicates the pres-
ence of a second lineage of potential lipid-recognizing
T cells in the human liver. These cells also released
IFN-, but not IL-4, in response to stimulation. In the
absence of identiWable markers of CD1c-restricted
cells, we do not know which T cell populations recog-
nise CD1c, but subpopulations of  T cells, most nota-
bly V1+ T cells, are known to be CD1c-restricted [37,
45, 53]. We have reported [32] that human liver is a rich
source of  T cells, which comprise »7% of hepatic
T cells with signiWcant numbers expressing V1, V2
and V3 TCR chains. It is possible that these cells
contribute to the CD1c-reactivity. However, not all
CD1c-reactive T cells are  T cells and several distinct
populations of  T cells can also recognise CD1c [40, 47];
therefore, it is likely that the repertoire of hepatic
CD1c-reactive T cells is heterogeneous.
CD1d-restricted NKT cells play key roles in anti-
tumour defence in mice. Injection of mice with either
IL-12 or GC results in tumour rejection by a mecha-
nism that is dependent upon IFN- production and/
or anti-tumour cytotoxicity by NKT cells [41, 50].
Furthermore, mice deWcient in CD1d or NKT cells fail
to mediate IL-12-induced rejection of tumours [14].
Numerical and functional deWciencies of NKT cells
have been reported in humans with tumours [15, 33, 55,
59]; therefore, we compared CD1 expression and T cell
reactivity against CD1 in liver samples from normal
donors and uninvolved liver tissue from patients with
metastatic liver disease. We found no signiWcant diVer-
ences in CD1a, CD1c or CD1d mRNA or protein
expression and no diVerences in hepatic T cell reactiv-
ity against these molecules in the two groups. We
found a signiWcant upregulation of intracellular CD1b
expression by MNC from tumour-bearing livers compared
with healthy livers. We observed a non-signiWcant
trend towards less CD1d- and more CD1c-reactivity in
tumour-bearing livers compared with normal controls,
which mirrors reductions of V24+V11+ NKT cells
and expansions of V1+ T cells which we have seen in
patients with hepatic malignancy [32, 33].
Our data provide evidence that the adult human
liver is a site of accumulation of autoreactive T cells
that respond to CD1c or CD1d by releasing IFN-. T
cells that recognise CD1c and CD1d have been shown
to play immunostimulatory roles at early stages of
immune responses by responding to self-lipids pre-
sented by immature dendritic cells. Upon exposure
to microbial products, such as lipopolysaccharide, den-
dritic cells secrete proinXammatory cytokines (IL-12)
that amplify weak responses of invariant NKT cells
to CD1d-presented self-antigens [8]. Thus NKT cells
can become activated in many diVerent microbial
infections, resulting in the release of chemokines and
cytokines that promote recruitment and activation of
macrophages, NK cells, T cells and B cells. CD1a–d-
restricted T cells can also reciprocally induce matura-
tion of dendritic cells and their release of IL-12 [35, 37,
56, 58]. The liver is notable for its ability to induce
immunological tolerance to dietary antigens entering
from the hepatic portal vein [13] despite having multi-
ple lymphocyte populations that display potent Th1
activities ex vivo [16, 43]. Autoreactive CD1-restricted
T cells could provide mechanisms whereby active
immunity can be rapidly induced within this tolero-
genic environment, by maintaining a low level of
autoreactivity that can be upregulated in response
to pathogens.123
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